TY - JOUR
AU - Shaw, Robert H.
AU - Liu, Xinxue
AU - Stuart, Arabella S.V.
AU - Greenland, Melanie
AU - Aley, Parvinder K.
AU - Andrews, Nick
AU - Cameron, J. Claire
AU - Charlton, Sue
AU - Clutterbuck, Elizabeth A.
AU - Collins, Andrea M.
AU - Dejnirattisai, Wanwisa
AU - Dinesh, Tanya
AU - Faust, Saul N.
AU - Ferreira, Daniela M.
AU - Finn, Adam
AU - Green, Christopher A.
AU - Hallis, Bassam
AU - Heath, Paul T.
AU - Hill, Helen C.
AU - Lambe, Teresa
AU - Lazarus, Rajeka
AU - Libri, Vincenzo
AU - Long, Fei
AU - Mujadidi, Yama F.
AU - Plested, Emma
AU - Morey, Ella
AU - Provstgaard-Morys, Samuel
AU - Ramasamy, Maheshi N.
AU - Ramsay, Mary E.
AU - Read, Robert C.
AU - Robinson, Hannah
AU - Screaton, Gavin R
AU - Singh, Nisha
AU - Turner, David P.J.
AU - Turner, Paul J.
AU - Vichos, Jason
AU - Walker, Laura
AU - White, Rachel
AU - Nguyen-Van-Tam, Jonathan S.
AU - Snape, Matthew D.
AU - Com-COV Study Group
PY - 2022
DA - June
TI - Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
JO - The Lancet Respiratory Medicine
DO - https://doi.org/10.1016/S2213-2600(22)00163-1
AB - ackgroundPriming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com-COV trial, assessing the effect of 4-week versus 12-week priming intervals onreactogenicityand the persistence of immune response up to 6 months after homologous and heterologous priming schedules using the vaccines BNT162b2 (tozinameran, Pfizer/BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca).
PB - Elsevier
UR - https://publichealthscotland.scot/id/90396
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
ER